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TO THE EDITOR
Xeroderma pigmentosum complemen-
tation group E (XP-E) patients exhibit
sunlight-induced lentiginous pigmen-
tation without blistering on minimal
sun exposure, yet they are prone to
develop multiple skin cancers. Only
eight XP-E patients have been reported
(Bootsma et al., 1970; De Weerd-
Kastelein et al., 1974; Kraemer et al.,
1975; Nichols et al., 1996; Rapic
et al., 1998; Itoh et al., 1999, 2000;
Rapic-Otrin et al., 2003) with mutations
in the DDB2 gene (Tang and Chu,
2002; Itoh, 2006), resulting in the loss
of UV-damaged DNA-binding protein
(UV-DDB) activity (Nichols et al., 2000;
Rapic-Otrin et al., 2003) (Table 1). UV-
DDB is a heterodimer of DDB1 (p127)
and DDB2 (p48) (Keeney et al., 1994;
Kazantsev et al., 1996) that binds with
high affinity to DNA damaged by UV and
is involved in initiation of global genome
nucleotide excision repair (GG-NER)
(Sugasawa, 2010).
We identified four adult XP-E pa-
tients from three kindreds with large
numbers of skin cancers (Table 1).
Patients’ written, informed consent
was obtained. The Declaration of
Helsinki guidelines were followed and
all necessary institutional approvals
were obtained. Patient XP1GO, 45
years old, in family A from Germany
never experienced a blistering sunburn
(Figure 1a). Diagnosed with XP at
age 22, he works as a train conductor.
His first tumor was removed at age 12.
He had 4400 basal cell carcinomas
(BCCs) and squamous cell carcinoma
(SCCs) and 6 melanomas treated by age
30, and now he develops B20 skin
cancers per year. He has no neurologi-
cal abnormalities. Patient XP37BE is a
45-year-old Caucasian female of Dutch
ancestry in family B living in the
western United States (Figure 1b). She
denies ever having a blistering sunburn.
She developed a keratoacanthoma on
her face at 7 years and was diagnosed
with XP. XP37BE has had 4300 BCC
and SCC skin cancers but no melano-
mas. She has no neurological abnorm-
alities. Patient XP66BE is a 43-year-old
brother of XP37BE. He was diagnosed
with XP at age 4 at the same time his
older sister was diagnosed and exhibits
similar clinical symptoms, yet, milder
because of improved sun protection.
Patient XP408BE is a 53-year-old Cau-
casian female in family C from the
eastern United States (Figure 1c). She
had no sunburns and tanned easily, but
did experience significant photophobia.
At age 14, she was found to have
multiple skin cancers (BCCs and SCCs)
on her face and a diagnosis of XP was
made. She has no XP neurological
abnormalities.
All cells were either established at
the Human Genetic Mutant Cell Repo-
sitory, the NCI Repository, or in the
Department of Dermatology, Goettin-
gen, Germany. Plasmid host cell
reactivation assay was performed for
cellular DNA repair capacity measure-
ment (Emmert et al., 2000). The cells
were transfected with a UV-treated
plasmid containing a reporter (lucifer-
ase) gene (pCMVLuc). Compared with
normal and XP variant cells, XP1GO,
XP37BE, XP66BE, and XP408BE/
GM01389 cells had a reduced level of
luciferase expression whereas severe
XP-B control cells had an even lower
level (data not shown). To determine
the complementation group we co-
transfected the UV-irradiated pCMVLuc
with plasmids that carry cloned wild-
type XP complementary DNA (cDNA).
Only co-transfection of the DDB2
cDNA resulted in markedly enhanced
reporter gene activities (data not
shown).
Human primary XP-E fibroblasts have
been reported to show abnormally low
or undetectable levels of p53 and its
downstream-regulated proteins (Hwang
et al., 1999; Itoh et al., 2003; Itoh, 2006).
In agreement with this observation, the
intensities of p53 and p21 bands were
reducedB60–80% and 40–60%, respec-
tively, in untreated XP37BE, XP66BE,
and XP408BE/GM01389 cells (ECL
Abbreviations: BCC, basal cell carcinoma; cDNA, complementary DNA; GG-NER, global genome
nucleotide excision repair; SCC, squamous cell carcinoma; SNP, single-nucleotide polymorphism
STR, short tandem repeat; UV-DDB, UV-damaged DNA-binding protein; XP-E, xeroderma
pigmentosum complementation group E
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Western blotting; Amersham, Piscat-
away, NJ) (data not shown).
Sequence analysis (NC_000011.8
for genomic sequence, NM_000107.1
for cDNA, and NP_000098.1 for pro-
tein) revealed a, to our knowledge
previously unreported, homozygous
C-to-A transversion (c.914 C4A) in
exon 7 in the DDB2 gene of XP1GO.
This missense mutation resulted in a
p.Thr305Asn substitution (Table 1). His
parents and brother were heterozygous
for this mutation. The restriction en-
zyme BtgI cuts the normal but not the
mutant sequence.
XP37BE and XP66BE showed homo-
zygous G-to-A transitions in exon 6 of
DDB2. This missense mutation (c.818
G4A) resulted in p.Arg273His and
was also found in their mother and
father but not their unaffected brother
(Table 1). This mutation inactivates a
HhaI restriction site. This mutation
was previously reported in XP2RO and
XP3RO cells from the Netherlands
(Bootsma et al., 1970; De Weerd-
Kastelein et al., 1974; Kraemer et al.,
1975; Nichols et al., 1996).
The cells from patient XP408BE had
compound heterozygous mutations in
exon 8. One allele showed a T-to-C
transversion (c.1049 T4C) resulting in
p.Leu350Pro, and the other allele had a
Table 1. Clinical features and DDB2 mutations
DDB2 mutations1
Allele 1 Allele 2
Family Cell line
Last
reported
age/sex Location Clinical features cDNA Amino acid
Size
(aa)2 cDNA Amino acid
Size
(aa)2 References6
A XP1GO 45y/M Germany 4400 BCCs and
SCCs; 6 melanomas
before age 30
c.914 C4A
(exon 7)
pThr305Asn 427 Homozygous This paper
B XP37BE3 45y/F USA/the
Netherlands
4300 BCCs and
SCCs, no melanomas
c.818 G4A
(exon 6)
p.Arg273His 427 Homozygous This paper
B XP66BE3 43y/M USA/the
Netherlands
6 Melanomas before
age 40
c.818 G4A
(exon 6)
p.Arg273His 427 Homozygous This paper
C XP408BE4 53y/F USA 4600 BCCs, SCCs,
and 12 melanomas
by age 50
c.1049 T4C
(exon 8)
p.Leu350Pro 427 c.1045_1047del
(exon 8)
p.Asn349del 426 This paper
C GM013894 21y/F USA Multiple skin cancers c.1049 T4C
(exon 8)
p.Leu350Pro 427 c.1045_1047del
(exon 8)
p.Asn349del 426 A
D XP2RO5 34y/F The
Netherlands
Skin cancer developed
at age 14
c.818 G4A
(exon 6)
p.Arg273His 427 Homozygous B, C, E
D XP3RO5 29y/F The
Netherlands
Skin cancer present c.818 G4A
(exon 6)
p.Arg273His 427 Homozygous B, C, E
E XP82TO 41y/F Japan No skin cancer c.730 A4G
(exon 6)
p.Lys244Glu 427 Homozygous B
F XP23PV 18y/M Italy 7 BCCs from age
16 to 18
c.703_1023del
(del. exon 6
and 7)
p.Leu235_Lys341del 320 Homozygous A, D
G XP25PV 29y/F Italy 5 BCCs and 1 SCC
from age 22 to 28
c.919 G4T
(exon 7)
c.918 G4A
(exon 7)
p.Asp307Tyr
No change
427
427
Homozygous
Homozygous
A, D
H XP27PV 35y/F Italy BCC, SCC, and
melanoma
1. c.730_733del
(exon 6)
2. c.703_880
(del. exon 6)
3. c.703_1023del
(del. exon 6 and 7)
p.Lys244X
p.Trp236Valfs*10
p.Leu235_Lys341del
243
244
320
Homozygous
Homozygous
Homozygous
A
I Ops1 62y/F Japan 14 BCCs and 5
melanomas on face,
2 SCC extremities
c.937 C4T
(exon 7)
p.Arg313X 312 Homozygous F
Abbreviations: BCC, basal cell carcinoma; cDNA, complementary DNA; DDB, DNA-binding protein; SCC, squamous cell carcinoma.
1GenBank reference sequence NC_000011.8 for genomic sequence, NM_000107.1 for cDNA, and NP_000098.1 for protein.
2Predicted size.
3Siblings.
4Same patient, cultures established at different ages (see text for details).
5Second cousins.
6References: A, Rapic-Otrin et al. (2003); B, Nichols et al. (2000); C, Bootsma et al. (1970); D, Rapic et al. (1998); E, Kraemer et al. (1975); F, Itoh et al.
(1999).
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three-base deletion (c.1045_1047del)
resulting in p.Asn349del (Table 1).
These two mutations were identical to
the mutations previously reported in
cell line GM01389 (Nichols et al.,
2000). We measured 15 single-nucleo-
tide polymorphisms (SNPs) in the
DDB2 gene to determine the relation-
ship between these two cell lines
(XP408BE and GM01389). All 15 SNPs
were identical in both cells (data not
shown). CODIS DNA fingerprinting
of highly polymorphic short tandem
repeats (STRs) was then performed
(Azari et al., 2007). All 13 CODIS core
STR loci were detected and were
identical in both cell lines (data not
shown). Thus, the likelihood that the
cells are not identical is approximately
one in one billion. Indeed, the patient
recalled having a skin biopsy for
fibroblast culture when she was 21
years old.
Figure 1d shows the crystal structure
of DDB2 stabilized by DDB1 and
contacting the damaged DNA exten-
sively (Chu and Yang, 2008; Scrima
et al., 2008). The heterozygous DDB2
mutations (Leu350Pro and Asn349del)
in XP408BE impair DDB1 binding
(DDB1–DDB2 interface mutations).
In contrast, the Arg273His mutation
in XP37BE and XP66BE directly
interferes with DNA binding (DNA-
binding mutation). The new mutation,
p.Thr305Asn in XP1GO cells, is located
in the WD domain near a known
Asp307Tyr mutation. This mutation
has been reported to disrupt damage
detection and complex formation with
DDB1 (Rapic et al., 1998; Rapic-Otrin
et al., 2003).
The diagnosis of XP-E can be con-
sidered in adults with freckle-like pig-
mentation without blistering on
minimal sun exposure who have many
skin cancers.
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TO THE EDITOR
Grouped patterns of pigmented lesions
are infrequent. Here, we analyze a rare
case of segmentally distributed, agmi-
nated nevi characterized by multiple
densely clustered lesions that are con-
fined to a developmental segment.
In fact, most segmental nevi are not
agminated (Happle, 2002) and arise
because of perturbations in the proli-
feration, migration, and differentiation
of embryological precursors, including
melanocytes (Misago et al., 1991; Sun
and Tsao, 2008). The unusual growth
pattern suggests mosaicism, i.e., a con-
dition whereby an organism is com-
posed of two genetically distinct cell
populations due to a post-zygotic muta-
tion (Itin and Burger, 2009). Cutaneous
mosaicism often manifests as lines of
Blaschko, a checkerboard pattern, or a
phylloid (leaf-like) pattern (Happle,
1993).
Recently, mutational analyses of
melanocytic nevi have revealed that
congenital moles, common acquired
nevi, Spitz nevi, and blue nevi are
associated with significant mutation
rates in NRAS (Bauer et al., 2007),
BRAF (Pollock et al., 2003), HRAS (Da
Forno et al., 2009), and GNAQ (Van
Raamsdonk et al., 2009), respectively.
These findings suggest that mutational
activation of specific signaling mole-
cules drives the formation of these nevi.
We thus hypothesized that our patient’s
agminated segmental nevi (ASN) resul-
ted from a mosaic event related to one
of the known RAS effectors.
The patient is a 58-year-old man
who developed numerous grouped
nevi on his right leg shortly after birth.
There was no other significant personal
medical history or family history of
melanoma or dysplastic nevus syn-
drome. On examination of his right
thigh and calf, there was an extensive
band-like cluster of 4100 pigmented
macules, plaques, and papules clini-
cally consistent with junctional, com-
pound, or intradermal nevi (Figure 1a).
Background skin in the area showed no
hypo- or hyperpigmentation. Over mul-
tiple visits, 11 clinically atypical nevi
within the segment were removed
although none had histological features
of melanoma. Pathological evaluation
of the biopsies largely showed intra-
dermal nevi with congenital patterns
(Figure 1b).
This genetic study was approved by
the Research Ethics Board at Dalhousie
University, and was conducted accord-
ing to Declaration of Helsinki Princi-
ples. The patient also gave his written
informed consent. We analyzed the 11Abbreviations: ASN, agminated segmental nevi; CFC, cardio-facio-cutaneous
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